ZipLine Medical Secures $12 Million in New Financing Led by New Investor, HighCape Partners

Clinical Studies Continue to Show Better Scars, Shorter Procedure Times, Fewer Wound Complications and Reduced Post-Surgical Care Cost CAMPBELL, Calif.–(BUSINESS WIRE)–ZipLine Medical, Inc. today announced it completed a $12 million Series E round of financing. Proceeds from the financing will be used to continue worldwide commercialization activities for its Zip® Surgical Skin Closure products, as well as development of advanced tools to reduce post-discharge costs in a bundled care environment.

TELA Bio to Present Surgeon Feedback from Initial Clinical Experience with OviTex™ Reinforced BioScaffolds and Product Permeability Data at Abdominal Wall Reconstruction Conference

Surgeons experience clinical success with OviTex products in a wide range of hernia patients MALVERN, Pa., June 5, 2017 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company will present at the MedStar Georgetown University Hospital’s Abdominal Wall Reconstruction (AWR) Conference being held June 8-10 at the JW Marriott in Washington, D.C. OviTex RBSs

Aziyo Continues Building New Breed of Regenerative Medicine Company

SILVER SPRING, MD. – Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced it has completed an asset purchase agreement with CorMatrix® Cardiovascular, Inc. for the purchase of all CorMatrix commercial assets and related intellectual property. With the acquisition, Aziyo will: Add 5 commercially marketed products Double topline revenue Add 50 employees, including a direct sales organization of 37 professionals Welcome 2 highly experienced executives to its leadership

TELA Bio Initiates BRAVO Study of OviTex™ Reinforced BioScaffolds for Hernia Repair

Study to evaluate performance of OviTex Permanent 1S for treatment of ventral hernias. MALVERN, Pa., April 25, 2017 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company has initiated a post-market clinical study, BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair (BRAVO), of its OviTex™ Permanent 1S

TELA Bio to Participate in 16th Annual Needham Healthcare Conference

MALVERN, Pa., March 31, 2017 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of OviTex™ Reinforced BioScaffolds (RBSs) for soft tissue repair, announced today that the company will participate in the 16th Annual Needham Healthcare Conference to be held April 4-5, 2017 at the Westin NY Grand Central Hotel in New York City. Antony Koblish, president and CEO of TELA Bio, will present an

CHEETAH MEDICAL ANNOUNCES RESULTS OF KEY SEPSIS STUDY

March, 2017. NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a rapidly growing medical device company, announced the results of a major new study conducted by Drs. Heath Latham and Steven Q. Simpson from the University of Kansas Medical Center. The study was designed to evaluate fluid resuscitation in ICU patients with severe sepsis and septic shock, and results were presented this week at the International Symposium on Intensive Care and Emergency Medicine (ISICEM)

CHEETAH MEDICAL ADVANCES THE SCIENCE OF FLUID MANAGEMENT

December, 2016. NEWTON, Mass. –(BUSINESS WIRE)– Cheetah Medical announced today that its eighth abstract on fluid management will be presented at Society of Critical Care Medicine meeting in January. Building on previous work, this abstract demonstrates a strong association between large volume fluid administration in septic shock and increased risk of death in more than 23,000 patients. Each year, millions of patients require hemodynamic monitoring to ensure optimal volume and

TELA Bio Announces Settlement of Litigation with LifeCell

TELA Bio to maintain full rights to manufacture and sell its OviTex™ Reinforced BioScaffolds MALVERN, Pa., Nov. 21, 2016 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that it has settled all litigations and disputes between TELA Bio and LifeCell, and that all pending state and federal court actions between the two companies have been dismissed.

TELA Bio Announces OviTex™ Reinforced BioScaffolds Implanted in 100 Hernia Repair Procedures

Surgical mesh integrating polymer and biologic materials received FDA 510(k) clearance in June 2016. MALVERN, Pa., Nov. 1, 2016 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development and commercialization of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the company’s OviTex™ RBSs have been implanted in more than 100 hernia repair procedures since receiving U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2016.

Cheetah Medical Announces Supplier Agreement with Allina Health

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical has signed a supplier contract with Allina Health, a leading non-for-profit healthcare system serving communities throughout Minnesota and western Wisconsin. The contract enables Allina Health facilities to have access to Cheetah Medical’s hemodynamic monitoring solutions to guide volume management decisions in septic patients across the Allina Health hospital network. “Intravenous fluid requirements vary significantly between patients based on underlying health conditions, and it can be a

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

MALVERN, Pa., July 13, 2016 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug Administration (FDA) 510(K) clearance. OviTex RBSs feature an embedded polymer and an intact extracellular matrix (ECM), a biologic building

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

OviTex portfolio integrates interwoven polymer suture and biologic materials through innovative engineering design principles for soft tissue repair. MALVERN, Pa., July 13, 2016 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced the commercial launch of the company’s OviTex™ portfolio of products for use in ventral hernia repair and abdominal wall reconstruction following U.S. Food and Drug

Results from Studies of OviTex™ Reinforced BioScaffolds Presented at Abdominal Wall Reconstruction Conference

New class of surgical mesh demonstrates positive healing response, rapid graft integration in a non-human primate model. MALVERN, Pa., June 15, 2016 /PRNewswire/ — TELA Bio, Inc., a surgical reconstruction company leading the development of Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that results from three studies of the company’s OviTex™ RBSs were presented at the Abdominal Wall Reconstruction (AWR) Conference held June 9-11 in Washington, D.C. OviTex

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

BALTIMORE, MD — HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company, Aziyo Biologics, Inc. HighCape has partnered with Tissue Banks International (TBI) to create a regenerative medicine company focused on best-in-class leadership and technology. Deerfield Management Co. joined HighCape in providing capital for the transaction. Aziyo

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

BALTIMORE, Maryland, November 5, 2015 – HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, today announced it led the formation of and holds a majority interest in newly formed regenerative medicine company,

HighCape Partners Closes Initial $80 Million Growth Equity Fund

BALTIMORE, Maryland, September 16, 2015 – HighCape Partners Management, L.P. today announced the final closing of HighCape Partners, L.P., its initial $80 million growth equity fund focused on investing in commercial-stage life sciences companies.

Cheetah Medical Secures $5 Million Investment from HighCape Partners

Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013.  

Cheetah Medical appoints Massachusetts General Hospital physician, Douglas M. Hansell, MD, MPH, as Chief Physician Executive

Cheetah Medical has appointed Douglas M. Hansell, MD, MPH, Assistant Clinical Professor of Anesthesia at Massachusetts General Hospital, as Chief Physician Executive.

Study* Shows $3+ of Costs Can Be Avoided by Hospitals for Every $1 They Spend During Surgery by Using Noninvasive Hemodynamic Monitoring

Cheetah Medical announced that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.  

Cheetah Medical Expands Product Line, Introduces “Starling™ SV” Noninvasive Hemodynamic Monitoring System

Cheetah Medical has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasive hemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.

Cheetah Medical says its growth is outpacing global market for hemodynamic monitoring systems, expected to reach $1.1 billion by 2019, according to market research firm MarketsandMarkets

Cheetah Medical announced that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets.

CHEETAH MEDICAL INTRODUCES STARLING SV NONINVASIVE HEMODYNAMIC MONITORING SYSTEM

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a privately held and rapidly growing medical device company, announced today that it has expanded its product line and is now offering the FDA-cleared and CE-marked Starling™ SV—a noninvasivehemodynamic monitoring system that provides data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care. Dynamic IV fluid-assessment using the newly introduced Starling™ SV and the benchmark CHEETAH NICOM™ systems are the only

CHEETAH MEDICAL SAYS ITS GROWTH IS OUTPACING GLOBAL MARKET FOR HEMODYNAMIC MONITORING SYSTEMS

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a privately held and rapidly growing medical device company, announced today that its growth is outpacing the global hemodynamic monitoring systems market, which is expected to reach $1.1074 billion by 2019 at a CAGR of 4.5% during the forecast period, according to MarketsandMarkets, the world’s No. 2 firm in terms of annually published premium market research reports. According to MarketsandMarkets, the global hemodynamic systems market is

DUKE UNIVERSITY STUDY SHOWS $3+ OF COSTS AVOIDED FOR EVERY $1 THEY SPEND USING NONINVASIVE HEMODYNAMIC MONITORING DURING SURGERY

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a rapidly growing medical device company, announced today that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring. Use of noninvasive hemodynamic monitoring for assessing fluid responsiveness in a wide range of circulatory conditions

KEY CLINICIANS RECOGNIZE THE CLINICAL AND ECONOMIC BENEFITS OF NONINVASIVE VOLUME MANAGEMENT

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a rapidly growing medical device company, announced today that key opinion leading physicians are recognizing the significant clinical and economic benefits of noninvasive hemodynamic monitoring during perioperative fluid management. Cheetah Medical hosted a non-CME educational symposium —“Clinical and Economic Considerations of Non-Invasive Hemodynamic Monitoring in Perioperative Fluid Management”—on Sunday, Oct. 12, during the annual scientific meeting of the American Society of Anesthesiologists (ASA). Faculty included: Prof.

BOSTON BUSINESS JOURNAL SPEAKS TO CHEETAH MEDICAL CEO CHRIS HUTCHISON

Cheetah Medical Inc., a Newton-based company making non-invasive blood monitoring system, received $5 million in venture capitalist funding from HighCape Partners. Chris Hutchison, president and chief executive officer, said the company is already in over 200 hospitals in the U.S. and over 50 countries worldwide, but the funding will help fuel more commercial activities and increase clinical programs. “We’re at a stage where we’re going through a high rate of

CHEETAH MEDICAL SECURES $5 MILLION INVESTMENT FROM HIGHCAPE PARTNERS

NEWTON, Mass., June 6th, 2014 — Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, today announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013. HighCape is a growth equity firm with a specialized focus and partner expertise in transforming commercial-stage life sciences companies into sustainable businesses. This investment